AutoImmune Inc. has signed a long-term contract with ScientificProtein Laboratories for supply of Myloral, an oral tolerance therapy inPhase III trials in the U.S. for treatment of multiple sclerosis.Fred Bader, vice president of operations for the Lexington, Mass.-based AutoImmune, said financial terms of the agreement were notdisclosed. Scientific Protein, a Wisconsin-based subsidiary ofAmerican Home Products Corp., of Madison, N.J., has suppliedMyloral to AutoImmune since 1992.Bader said under the new agreement, Scientific Protein will continuesupplying the drug through the completion of clinical trials and intocommercialization if Myloral is approved for marketing.The Phase III studies, involving 500 multiple sclerosis patients, beganin March and will take two years to complete. Bader said about 300patients have been enrolled in the trials, which are being conducted at13 medical centers in the U.S. and Canada.Myloral, which was developed by AutoImmune, is an oral formulationof bovine myelin that is believed to reduce the severity of the disease.The primary endpoint of the trials is reduction in frequency of attacksin multiple sclerosis patients. _ Charles Craig

(c) 1997 American Health Consultants. All rights reserved.